JPRN-UMIN000015208已完成3 期
Double-blind, placebo-controlled study to evaluate adjuvanticity effects of Pleurotus cornucopiae extracts. - Adjuvanticity effects of Pleurotus cornucopiae extracts.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Subjects who are under medication for chronic ailments (especially diseases related to cancer, liver, kidney, heart, gastrointestinal tract, diabetes, hypertension, mental disorder etc) 2.Subjects with serious diseases or infections such as cerebrovascular, cardiac, liver, kidney, gastrointestinal tract or condition which need immediate reporting to the authorities 3.Subjects who are suspected of acute infection morbidity from diseases such as influenza 4.Subjects who undergo treatment for chronic inflammatory diseases autoimmune diseases or allergies etc 5.Subjects who receive vaccination 12 weeks before participating in this study or those who will get inoculated during this study period 6.Subjects who have a major surgical history such as gastrectomy, gastrointestinal suture surgery or intestinal resection etc 7.Subjects with frequent complaints of post-menopausal symptoms 8.Subjects with unusually high and/or low blood pressure, or with abnormal hematological data 9.Subjects with serious anemia 10.Subjects with a history of allergy to medicine and food (especially mushroom, soybean, wheat) 11.Subjects who regularly undertake medication which can affect the immune function (antibiotics, immunosuppressive drugs, anti-inflammatory drugs, anti-rheumatic drugs, antihistamines, anti-allergy drugs, lactic acid bacteria supplements etc.) Chinese herbal medicine, health food, supplements, extracts from (mushroom, seaweed, nucleic acids, yeast, lactic acid bacteria etc) 12.Heavy smokers, alcohol addicts or subjects with irregular lifestyle 13.Subjects who donate either 400ml whole blood within 12 weeks or plasma, platelets within 4 weeks or blood component within 2 weeks prior to this study 14.Subjects who are pregnant or under lactation or ones who would expect to be pregnant during the study 15.Subjects who participate in other clinical trials within the last one month prior to the current clinical trial 16.Subjects who are ineligible due to physician's judgment
研究者
相似试验
已完成
不适用
A double-blind, placebo-controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with symptoms of overactive bladderISRCTN97355181Plethora Solutions Ltd (UK)100
进行中（未招募）
1 期
A study to see how inhaled PC945 affects a fungal infection in patients with asthma or other lung diseases.Pulmonary aspergillosis and candidiasis of lungMedDRA version: 20.0Level: LLTClassification code 10059259Term: Pulmonary aspergillosisSystem Organ Class: 100000004862MedDRA version: 20.0Level: LLTClassification code 10007155Term: Candidiasis of lungSystem Organ Class: 100000004862EUCTR2018-000244-26-GBPulmocide Ltd46
进行中（未招募）
1 期
A double-blind, placebo controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients symptoms of overactive bladder (OAB)overactive bladder (OAB)MedDRA version: 8.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2006-001334-40-GBPLETHORA SOLUTIONS LIMITED112
进行中（未招募）
不适用
A double-blind, placebo controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients symptoms of overactive bladder (OAB)overactive bladder (OAB)MedDRA version: 8.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2006-001334-40-IEPLETHORA SOLUTIONS LIMITED112
已完成
不适用
A double-blind, placebo controlled study to assess the effects of early intervention and/or treatment with epoetin alfa on anaemia in cancer patients receiving non-platinum containing chemotherapyAnaemiaHaematological DisordersAnaemia in chronic diseases classified elsewhereISRCTN98318971Janssen-Cilag Ltd (UK)